Combination cancer chemotherapy with one compound: Pluripotent bradykinin antagonists

Peptides

Volumn 26, Issue 8, 2005, Pages 1288-1291

  Stewart, John M ^a   Gera, Lajos ^a   Chan, Daniel C ^a   York, Eunice J ^a   Simkeviciene, Vitalija ^a   Bunn Jr , Paul A ^a   Taraseviciene Stewart, Laimute ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiogenesis; Apoptosis; Bradykinin antagonist; Cancer; MMP inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; B 9430; B 9870; BKM 1174; BKM 1648; BKM 570; BKM 638; BRADYKININ; BRADYKININ ANTAGONIST; CISPLATIN; DOCETAXEL; ILOMASTAT; MATRIX METALLOPROTEINASE; SEMAXANIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRADYKININ; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; GUINEA PIGS; HUMANS; ILEUM; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; OLIGOPEPTIDES; PHENYLALANINE; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

MUS MUSCULUS;

EID: 22544471499     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.03.052     Document Type: Conference Paper

References (9)

1. D. Chan, L. Gera, J. Stewart, B. Helfrich, M. Verella-Garcia, and G. Johnson Bradykinin antagonist dimer CU-201 inhibits the growth of human lung cancer cells by a novel "biased agonist" mechanism Proc Natl Acad Sci USA 99 2002 4608 4613
2. D. Chan, L. Gera, J. Stewart, B. Helfrich, T.L. Zhao, and W.Y. Feng Bradykinin antagonist dimer CU-201 inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other anti-tumor agents Clin Cancer Res 8 2002 1280
3. K. Ishihara, M. Kamata, I. Hayashi, S. Yamashina, and M. Majima Roles of bradykinin in vascular permeability and angiogenesis in solid tumors Int Immunopharmacol 2 2002 499 509
4. J.M. Stewart Bradykinin antagonists as anti-cancer agents Curr Pharm Des. 9 2003 2036 2042
5. J.M. Stewart, L. Gera, D.C. Chan, P.A. Bunn Jr., E.J. York, and V. Simkeviciene Bradykinin-related compounds as new drugs for cancer and inflammation Can J Physiol Pharmacol 80 2002 275 280
6. J.M. Stewart, L. Gera, W. Hanson, J.S. Zuzack, M. Burkard, and R. McCullough A new generation of bradykinin antagonists Immunopharmacol 33 1996 51 60
7. J.M. Stewart, and J.D. Young Solid phase peptide synthesis 1984 Pierce Chemical Co. Rockford, IL
8. J. Wu, T. Akaike, T. Havashida, T. Okamoto, A. Okuvama, and H. Maeda Enhanced vascular permeability in solid tumors involving peroxynitrite and matrix metalloproteases Jpn J Cancer Res 92 2001 439 451
9. J. Wu, T. Akaike, and H. Maeda Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor and a nitric oxide scavenger Cancer Res 58 1998 159 165